To provide pharmaceutical compositions used to treat or prevent: epilepsy and related disorders; neuropathic pain; migraine or resistant headache; and bipolar and related disorders.SOLUTION: A pharmaceutical composition comprises: (a) a synaptic vesicle protein 2A (SV2A) ligand selected from the group consisting of levetiracetam, brivaracetam and seletracetam; and (b) a positive allosteric modulator (PAM) compound of metabotropic glutamatergic receptor subtype 2 (mGluR2) of the formula in the figure or a pharmaceutically acceptable salt or solvate thereof, or an orthosteric agonist compound of metabotropic glutamatergic receptor subtype 2 or a pharmaceutically acceptable salt or solvate thereof.SELECTED DRAWING: None
COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2, AND THEIR USE